Implantable monitor may help in managing diastolic heart failureDecember 11, 2008An implantable hemodynamic monitor (IHM) may help to guide medical treatment in a large subgroup of patients with heart failure-those with diastolic heart failure (DHF), reports a study in the December Journal of Cardiac Failure (http://www.onlinejcf.com/), published by Elsevier. Led by Michael R. Zile, M.D., of Medical University of South Carolina, Charleston, the researchers analyzed data on DHF patients enrolled in a larger randomized trial evaluating the IHM for heart failure. The IHM is a surgically implanted device that continuously records data on heart function and other key variables. The data can then be downloaded for analysis by health care professionals, who can use it to make adjustments in medical therapy. The goal is to avoid sudden drops in heart function, called acute decompensation. The main "COMPASS-HF" study included 274 patients with all types of heart failure. The original results showed that the risk of heart failure events was reduced by about 20 percent in patients treated with the IHM, although the difference was not statistically significant. The new analysis focused on the subgroup of patients with DHF. In DHF, the heart still has normal pumping function (ejection fraction), but no longer relaxes sufficiently to fill with blood normally. In the COMPASS-HF study, 70 patients with DHF were randomly assigned to receive the IHM, while the rest were managed without the IHM. As in the main study, DHF patients who received the IHM device had a 20 percent reduction in heart failure events, although the difference was not significant. A 29 percent reduction in the risk of hospitalization for heart failure was also nonsignificant. The IHM did lead to some significant changes in patient management, including more frequent adjustments in the dose of diuretics-a key part of treatment for heart failure. As in the larger study, the IHM device was safe in DHF patients, with a low complication rate. Patients with chronic heart failure need careful medical management to avoid episodes of acute decompensation. Few studies have focused on patients with DHF, even though they account for about half of all patients with heart failure. Based on the new analysis, there is as yet no evidence that using the IHM device to guide treatment reduces the risk of decompensation and heart failure events in patients with DHF. The IHM does appear safe for patients with heart failure, with a very low risk of complications. In addition, DHF patients receiving the IHM device show a trend toward lower rates of heart failure events, including hospitalization related to heart failure. "This is very important study and the trends make sense," comments Barry M. Massie, M.D., Editor-in-Chief of Journal of Cardiac Failure. "Worsening of HF leading to hospitalization, usually as a result of pulmonary congestion and rising blood pressure, is often more abrupt in patients with preserved ejection fraction. Hemodynamic monitoring may provide an early clue and facilitate relatively simple and effective interventions." Elsevier |
|||||||||||||||||||||
| Related Heart Failure Current Events and Heart Failure News Articles Researchers develop innovative imaging system to study sudden cardiac arrest A research team at Vanderbilt University has developed an innovative optical system to simultaneously image electrical activity and metabolic properties in the same region of a heart, to study the complex mechanisms that lead to sudden cardiac arrest. Experts unveil new CVD guidelines and position papers Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week. UT Southwestern patient first in North Texas to receive newest-generation heart failure device UT Southwestern Medical Center patient Michael LeBlanc, 40, is the first in North Texas to receive the newest generation of a mechanical device designed to improve heart function. It will be his lifeline while he awaits a heart transplant. Learning the risks for stroke - and taking action With this theme in mind, the European Society of Cardiology (ESC) emphasises that most of the risks for stroke are also the major risks for coronary heart disease - and thus the object of the ESC's far-reaching prevention programme. Concurrent imaging of metabolic and electric signals in the heart Cardiac rhythm disorders can result from disturbances in cardiac metabolism. These metabolic changes are tightly linked with specific cardiac electrophysiology (CEP) abnormalities, such as depressed excitability, impaired intra- and extracellular conductivities, wave propagation block, and alteration of conduction velocity, action potential amplitude, and duration. Canadian cardiology team clears the way for lifesaving breast cancer treatment A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society. 'Superobesity,' chronic disease burden associated with risk of death following bariatric surgery Veterans classified as superobese and those with a higher chronic disease burden appear more likely to die within a year of having bariatric surgery, according to a report in the October issue of Archives of Surgery, one of the JAMA/Archives journals. Thyroid surgery safe for older patients, study finds Thyroid surgery is safe for older patients, say physicians who found only slight differences in rates of complications and hospital readmissions in a multi-year study. New mathematical model more accurately diagnoses acute heart failure in emergency rooms Researchers at St. Michael's Hospital have developed the first mathematical model in cardiology and emergency medicine to more quickly and reliably diagnose acute heart failure (AHF) in emergency room patients. Cost Effectiveness of Blood Pressure Device Evaluated A study conducted by the University of Rochester Medical Center (URMC) demonstrates that, for certain patient populations, an experimental device that lowers blood pressure may be a cost effective treatment. The implantable device, called Rheos, is in advanced stages of testing for individuals with drug resistant hypertension. More Heart Failure Current Events and Heart Failure News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||